Search

Displaying results 7521 - 7530 of 10000 in total
  1. Drug

    Moricizine

    go.drugbank.com/drugs/DB00680
    ApprovedWithdrawn

    An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

  2. Drug

    Vinpocetine

    go.drugbank.com/drugs/DB12131
    Investigational

    Vinpocetine has been investigated for the treatment of Epilepsy.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Tefidsogene civaparvovec

    go.drugbank.com/drugs/DB16789
    Investigational

    It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes … Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.

    Synonyms: A RECOMBINANT NON-REPLICATING ADENO-ASSOCIATED VIRUS TYPE 2/6 (RAAV REP2-CAP6) VECTOR, WHICH CONTAINS A PROMOTER-LESS HUMAN IDURONATE 2-SULFATASE (HIDS) TRANSGENE CASSETTE, ENCODING PARTS OF EXON 1 PLUS, EXONS 2-9 FROM HIDS AND A SPLICE ACCEPTOR SITE (SA)
  4. Drug

    Aptazapine

    go.drugbank.com/drugs/DB09305
    Experimental

    Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. … It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine

  5. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases. … It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range.

    Categories: Phospholipases A, antagonists & inhibitors
  6. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). … In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers

  7. Drug

    SGX-523

    go.drugbank.com/drugs/DB06314
    Investigational

    A MET receptor tyrosine kinase inhibitor.

  8. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  9. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  10. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.